$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 138.91 | 54 | 7,501 | 41,579 | 41.6 K to 41.6 K (-0.13 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,000 | 0 | 41,633 | 36.6 K to 41.6 K (+13.65 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 138.91 | 1,000 | 138,910 | 46,785 | 47.8 K to 46.8 K (-2.09 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 7,000 | 0 | 47,785 | 40.8 K to 47.8 K (+17.16 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Option Exercise | A | 140.16 | 21,000 | 2,943,360 | 21,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 138.91 | 329 | 45,701 | 16,886 | 17.2 K to 16.9 K (-1.91 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Grant | A | 0.00 | 3,000 | 0 | 17,215 | 14.2 K to 17.2 K (+21.10 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 138.91 | 905 | 125,714 | 43,799 | 44.7 K to 43.8 K (-2.02 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 141.23 | 2 | 282 | 178,740 | 178.7 K to 178.7 K (0.00 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 138.91 | 1,120 | 155,579 | 178,742 | 179.9 K to 178.7 K (-0.62 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 8,000 | 0 | 179,862 | 171.9 K to 179.9 K (+4.65 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 138.91 | 663 | 92,097 | 36,685 | 37.3 K to 36.7 K (-1.78 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 7,000 | 0 | 37,348 | 30.3 K to 37.3 K (+23.07 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 140.65 | 1 | 141 | 52,278 | 52.3 K to 52.3 K (0.00 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 138.91 | 1,200 | 166,692 | 52,279 | 53.5 K to 52.3 K (-2.24 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 5,000 | 0 | 53,479 | 48.5 K to 53.5 K (+10.31 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 138.91 | 1,312 | 182,250 | 39,742 | 41.1 K to 39.7 K (-3.20 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Grant | A | 0.00 | 7,000 | 0 | 41,054 | 34.1 K to 41.1 K (+20.56 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Option Exercise | A | 140.16 | 131,000 | 18,360,960 | 131,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 141.45 | 14 | 1,980 | 191,012 | 191 K to 191 K (-0.01 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 138.91 | 2,000 | 277,820 | 191,026 | 193 K to 191 K (-1.04 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Grant | A | 0.00 | 20,000 | 0 | 193,026 | 173 K to 193 K (+11.56 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 140.58 | 25 | 3,515 | 742,197 | 742.2 K to 742.2 K (0.00 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 138.91 | 3,970 | 551,473 | 742,222 | 746.2 K to 742.2 K (-0.53 %) |
Feb 18 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 143.49 | 187 | 26,833 | 36,633 | 36.8 K to 36.6 K (-0.51 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,802 | 0 | 36,820 | 28 K to 36.8 K (+31.42 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 138.02 | 2,418 | 333,732 | 48,501 | 50.9 K to 48.5 K (-4.75 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 140.21 | 78 | 10,936 | 50,919 | 51 K to 50.9 K (-0.15 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 138.02 | 137 | 18,909 | 50,997 | 51.1 K to 51 K (-0.27 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 141.75 | 433 | 61,378 | 51,134 | 51.6 K to 51.1 K (-0.84 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 142.18 | 436 | 61,990 | 51,567 | 52 K to 51.6 K (-0.84 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 143.44 | 200 | 28,688 | 52,003 | 52.2 K to 52 K (-0.38 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 144.39 | 400 | 57,756 | 52,203 | 52.6 K to 52.2 K (-0.76 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 145.27 | 500 | 72,635 | 52,603 | 53.1 K to 52.6 K (-0.94 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 11,763 | 0 | 53,103 | 41.3 K to 53.1 K (+28.45 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 141.23 | 328 | 46,323 | 14,215 | 14.5 K to 14.2 K (-2.26 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 142.17 | 200 | 28,434 | 14,543 | 14.7 K to 14.5 K (-1.36 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 143.46 | 182 | 26,110 | 14,743 | 14.9 K to 14.7 K (-1.22 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 144.40 | 141 | 20,360 | 14,925 | 15.1 K to 14.9 K (-0.94 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 145.43 | 200 | 29,086 | 15,066 | 15.3 K to 15.1 K (-1.31 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Grant | A | 0.00 | 8,802 | 0 | 15,266 | 6.5 K to 15.3 K (+136.17 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 138.02 | 3,492 | 481,966 | 173,026 | 176.5 K to 173 K (-1.98 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 139.18 | 117 | 16,284 | 176,518 | 176.6 K to 176.5 K (-0.07 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 138.02 | 337 | 46,513 | 176,635 | 177 K to 176.6 K (-0.19 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 140.49 | 1,490 | 209,330 | 176,972 | 178.5 K to 177 K (-0.83 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 141.40 | 3,710 | 524,594 | 178,462 | 182.2 K to 178.5 K (-2.04 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 142.35 | 712 | 101,353 | 182,172 | 182.9 K to 182.2 K (-0.39 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 143.45 | 300 | 43,035 | 182,884 | 183.2 K to 182.9 K (-0.16 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 144.45 | 400 | 57,780 | 183,184 | 183.6 K to 183.2 K (-0.22 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 145.01 | 110 | 15,951 | 183,584 | 183.7 K to 183.6 K (-0.06 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Grant | A | 0.00 | 41,136 | 0 | 183,694 | 142.6 K to 183.7 K (+28.86 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 145.05 | 10 | 1,451 | 142,558 | 142.6 K to 142.6 K (-0.01 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 143.81 | 619 | 89,018 | 142,568 | 143.2 K to 142.6 K (-0.43 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 138.02 | 664 | 91,645 | 29,937 | 30.6 K to 29.9 K (-2.17 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 139.84 | 28 | 3,916 | 30,601 | 30.6 K to 30.6 K (-0.09 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 138.02 | 250 | 34,505 | 30,629 | 30.9 K to 30.6 K (-0.81 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 141.55 | 277 | 39,209 | 30,879 | 31.2 K to 30.9 K (-0.89 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 142.11 | 200 | 28,422 | 31,156 | 31.4 K to 31.2 K (-0.64 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 143.31 | 220 | 31,528 | 31,356 | 31.6 K to 31.4 K (-0.70 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 144.56 | 100 | 14,456 | 31,576 | 31.7 K to 31.6 K (-0.32 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 145.46 | 200 | 29,092 | 31,676 | 31.9 K to 31.7 K (-0.63 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 6,129 | 0 | 31,876 | 25.7 K to 31.9 K (+23.80 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 145.40 | 3 | 436 | 25,747 | 25.8 K to 25.7 K (-0.01 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 143.81 | 166 | 23,872 | 25,750 | 25.9 K to 25.8 K (-0.64 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 138.02 | 2,401 | 331,386 | 34,054 | 36.5 K to 34.1 K (-6.59 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 139.13 | 79 | 10,991 | 36,455 | 36.5 K to 36.5 K (-0.22 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 138.02 | 185 | 25,534 | 36,534 | 36.7 K to 36.5 K (-0.50 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 140.44 | 933 | 131,031 | 36,719 | 37.7 K to 36.7 K (-2.48 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 141.42 | 400 | 56,568 | 37,652 | 38.1 K to 37.7 K (-1.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 142.15 | 160 | 22,744 | 38,052 | 38.2 K to 38.1 K (-0.42 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 143.58 | 100 | 14,358 | 38,212 | 38.3 K to 38.2 K (-0.26 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 144.33 | 300 | 43,299 | 38,312 | 38.6 K to 38.3 K (-0.78 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 145.38 | 100 | 14,538 | 38,612 | 38.7 K to 38.6 K (-0.26 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Grant | A | 0.00 | 11,763 | 0 | 38,712 | 26.9 K to 38.7 K (+43.65 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 145.13 | 4 | 581 | 26,949 | 27 K to 26.9 K (-0.01 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 143.81 | 203 | 29,193 | 26,953 | 27.2 K to 27 K (-0.75 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 140.34 | 345 | 48,417 | 746,192 | 746.5 K to 746.2 K (-0.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 138.02 | 10,092 | 1,392,898 | 746,537 | 756.6 K to 746.5 K (-1.33 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 138.02 | 1,037 | 143,127 | 756,629 | 757.7 K to 756.6 K (-0.14 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 140.83 | 44 | 6,197 | 757,666 | 757.7 K to 757.7 K (-0.01 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 141.38 | 592 | 83,697 | 757,710 | 758.3 K to 757.7 K (-0.08 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 142.26 | 400 | 56,904 | 758,302 | 758.7 K to 758.3 K (-0.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 143.39 | 300 | 43,017 | 758,702 | 759 K to 758.7 K (-0.04 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.32 | 400 | 57,728 | 759,002 | 759.4 K to 759 K (-0.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 145.40 | 400 | 58,160 | 759,402 | 759.8 K to 759.4 K (-0.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Grant | A | 0.00 | 12,805 | 0 | 759,802 | 747 K to 759.8 K (+1.71 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.95 | 35 | 5,073 | 746,997 | 747 K to 747 K (0.00 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 143.81 | 2,227 | 320,265 | 747,032 | 749.3 K to 747 K (-0.30 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 138.02 | 1,430 | 197,369 | 44,704 | 46.1 K to 44.7 K (-3.10 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 139.77 | 44 | 6,150 | 46,134 | 46.2 K to 46.1 K (-0.10 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 141.77 | 434 | 61,528 | 46,178 | 46.6 K to 46.2 K (-0.93 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 142.12 | 400 | 56,848 | 46,612 | 47 K to 46.6 K (-0.85 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 143.61 | 300 | 43,083 | 47,012 | 47.3 K to 47 K (-0.63 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 144.34 | 400 | 57,736 | 47,312 | 47.7 K to 47.3 K (-0.84 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 145.49 | 400 | 58,196 | 47,712 | 48.1 K to 47.7 K (-0.83 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 146.38 | 36 | 5,270 | 48,112 | 48.1 K to 48.1 K (-0.07 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Grant | A | 0.00 | 11,763 | 0 | 48,148 | 36.4 K to 48.1 K (+32.33 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 138.02 | 3,487 | 481,276 | 171,862 | 175.3 K to 171.9 K (-1.99 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 139.23 | 116 | 16,151 | 175,349 | 175.5 K to 175.3 K (-0.07 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 132.02 | 287 | 37,890 | 175,465 | 175.8 K to 175.5 K (-0.16 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 141.79 | 419 | 59,410 | 175,752 | 176.2 K to 175.8 K (-0.24 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 142.25 | 435 | 61,879 | 176,171 | 176.6 K to 176.2 K (-0.25 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 143.51 | 200 | 28,702 | 176,606 | 176.8 K to 176.6 K (-0.11 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 144.36 | 500 | 72,180 | 176,806 | 177.3 K to 176.8 K (-0.28 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 145.37 | 300 | 43,611 | 177,306 | 177.6 K to 177.3 K (-0.17 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 146.22 | 100 | 14,622 | 177,606 | 177.7 K to 177.6 K (-0.06 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 11,763 | 0 | 177,706 | 165.9 K to 177.7 K (+7.09 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 145.40 | 11 | 1,599 | 165,943 | 166 K to 165.9 K (-0.01 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 143.81 | 692 | 99,517 | 165,954 | 166.6 K to 166 K (-0.42 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 138.02 | 1,908 | 263,342 | 40,785 | 42.7 K to 40.8 K (-4.47 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 140.32 | 58 | 8,139 | 42,693 | 42.8 K to 42.7 K (-0.14 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 140.47 | 1,043 | 146,510 | 42,751 | 43.8 K to 42.8 K (-2.38 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 141.19 | 400 | 56,476 | 43,794 | 44.2 K to 43.8 K (-0.91 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 142.11 | 100 | 14,211 | 44,194 | 44.3 K to 44.2 K (-0.23 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 143.53 | 100 | 14,353 | 44,294 | 44.4 K to 44.3 K (-0.23 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 144.40 | 362 | 52,273 | 44,394 | 44.8 K to 44.4 K (-0.81 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Buy | S | 145.54 | 100 | 14,554 | 44,756 | 44.7 K to 44.8 K (+0.22 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 11,763 | 0 | 44,656 | 32.9 K to 44.7 K (+35.76 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 138.02 | 755 | 104,205 | 30,348 | 31.1 K to 30.3 K (-2.43 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 139.75 | 23 | 3,214 | 31,103 | 31.1 K to 31.1 K (-0.07 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 141.54 | 530 | 75,016 | 31,126 | 31.7 K to 31.1 K (-1.67 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 142.33 | 499 | 71,023 | 31,656 | 32.2 K to 31.7 K (-1.55 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 143.46 | 351 | 50,354 | 32,155 | 32.5 K to 32.2 K (-1.08 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 144.53 | 352 | 50,875 | 32,506 | 32.9 K to 32.5 K (-1.07 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 145.55 | 348 | 50,651 | 32,858 | 33.2 K to 32.9 K (-1.05 %) |
Feb 08 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 11,763 | 0 | 33,206 | 21.4 K to 33.2 K (+54.86 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 28,968 | 663,367 | 153,950 | |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 400 | 9,160 | 182,918 | |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 5,632 | 128,973 | 183,318 | |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 191.14 | 12,086 | 2,310,118 | 749,259 | 761.3 K to 749.3 K (-1.59 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 190.55 | 16,882 | 3,216,865 | 761,345 | 778.2 K to 761.3 K (-2.17 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 28,968 | 663,367 | 778,227 | 749.3 K to 778.2 K (+3.87 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 190.15 | 400 | 76,060 | 749,259 | 749.7 K to 749.3 K (-0.05 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 400 | 9,160 | 749,659 | 749.3 K to 749.7 K (+0.05 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 190.00 | 5,632 | 1,070,080 | 749,259 | 754.9 K to 749.3 K (-0.75 %) |
Dec 29 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 5,632 | 128,973 | 754,891 | 749.3 K to 754.9 K (+0.75 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 70,000 | 1,603,000 | 188,950 | |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 189.73 | 3,596 | 682,269 | 749,259 | 752.9 K to 749.3 K (-0.48 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 188.80 | 17,903 | 3,380,086 | 752,855 | 770.8 K to 752.9 K (-2.32 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 188.14 | 16,289 | 3,064,612 | 770,758 | 787 K to 770.8 K (-2.07 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 186.87 | 19,801 | 3,700,213 | 787,047 | 806.8 K to 787 K (-2.45 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 186.19 | 12,411 | 2,310,804 | 806,848 | 819.3 K to 806.8 K (-1.51 %) |
Dec 21 2015 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 70,000 | 1,603,000 | 819,259 | 749.3 K to 819.3 K (+9.34 %) |
Dec 15 2015 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | S | 188.24 | 9,833 | 1,850,964 | 32,481 | 42.3 K to 32.5 K (-23.24 %) |
Dec 15 2015 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | S | 187.57 | 35,575 | 6,672,803 | 42,314 | 77.9 K to 42.3 K (-45.67 %) |